To the extent possible under law, AOP-Wiki has waived all copyright and related or neighboring rights to KE:1670
Key Event Title
|Level of Biological Organization|
Key Event Components
Key Event Overview
AOPs Including This Key Event
|AOP Name||Role of event in AOP||Point of Contact||Author Status||OECD Status|
|Frustrated phagocytosis-induced lung cancer||AdverseOutcome||Arthur Author (send email)||Under development: Not open for comment. Do not cite||Under Development|
|AHR activation leading to lung cancer via IL-6 tox path||AdverseOutcome||Cataia Ives (send email)||Under development: Not open for comment. Do not cite|
|AHR activation leading to lung cancer via AHR-ARNT tox path||AdverseOutcome||Brendan Ferreri-Hanberry (send email)||Under development: Not open for comment. Do not cite|
|AHR leading to lung cancer via NRF2 tox path||KeyEvent||Allie Always (send email)||Under development: Not open for comment. Do not cite|
Key Event Description
Lung cancer is one of the most prevalent cancer in the world. This cancer occur mainly at the level of bronchial cells and affect more rarely at the level of alveoli. Lung cancer affects more men rather than women because of tabacco consumption (trend is reversing). This disease is at the first place on terms of mortality due to the late detection (Cancer League, WHO).
How It Is Measured or Detected
Lung cancer can be measured in human by analysis of the sputum cytology, the chest X-ray and all the techniques usually used in this medical field.
In animal experiments, the OECD guidelines n°451 provide the procedure for the study of carcinogenesis development.
Domain of Applicability
Lung cancer can occur in mammals, male or female, generally in adults